| T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model A Di Stasi, B De Angelis, CM Rooney, L Zhang, A Mahendravada, ... Blood, The Journal of the American Society of Hematology 113 (25), 6392-6402, 2009 | 606 | 2009 |
| GD2-CART01 for relapsed or refractory high-risk neuroblastoma F Del Bufalo, B De Angelis, I Caruana, G Del Baldo, MA De Ioris, A Serra, ... New England Journal of Medicine 388 (14), 1284-1295, 2023 | 310 | 2023 |
| Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia C Quintarelli, G Dotti, B De Angelis, V Hoyos, M Mims, L Luciano, ... Blood, The Journal of the American Society of Hematology 112 (5), 1876-1885, 2008 | 153 | 2008 |
| Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma C Quintarelli, D Orlando, I Boffa, M Guercio, VA Polito, A Petretto, ... Oncoimmunology 7 (6), e1433518, 2018 | 152 | 2018 |
| Human CAR NK cells: a new non-viral method allowing high efficient transfection and strong tumor cell killing T Ingegnere, FR Mariotti, A Pelosi, C Quintarelli, B De Angelis, N Tumino, ... Frontiers in immunology 10, 957, 2019 | 126 | 2019 |
| High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells C Quintarelli, G Dotti, ST Hasan, B De Angelis, V Hoyos, S Errichiello, ... Blood, The Journal of the American Society of Hematology 117 (12), 3353-3362, 2011 | 116 | 2011 |
| ADAR1 is a new target of METTL3 and plays a pro-oncogenic role in glioblastoma by an editing-independent mechanism V Tassinari, V Cesarini, S Tomaselli, Z Ianniello, DA Silvestris, ... Genome biology 22, 1-22, 2021 | 104 | 2021 |
| Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model P Bocca, E Di Carlo, I Caruana, L Emionite, M Cilli, B De Angelis, ... Oncoimmunology 7 (1), e1378843, 2018 | 103 | 2018 |
| Generation of Epstein-Barr virus–specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506) B De Angelis, G Dotti, C Quintarelli, LE Huye, L Zhang, M Zhang, F Pane, ... Blood, The Journal of the American Society of Hematology 114 (23), 4784-4791, 2009 | 102 | 2009 |
| Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia C Quintarelli, S Sivori, S Caruso, S Carlomagno, M Falco, I Boffa, ... Leukemia 34 (4), 1102-1115, 2020 | 97 | 2020 |
| Interleukin 15 Provides Relief to CTLs from Regulatory T Cell–Mediated Inhibition: Implications for Adoptive T Cell–Based Therapies for Lymphoma SK Perna, B De Angelis, D Pagliara, ST Hasan, L Zhang, ... Clinical Cancer Research 19 (1), 106-117, 2013 | 93 | 2013 |
| Adoptive immunotherapy using PRAME-specific T cells in medulloblastoma D Orlando, E Miele, B De Angelis, M Guercio, I Boffa, M Sinibaldi, A Po, ... Cancer research 78 (12), 3337-3349, 2018 | 92 | 2018 |
| Zoledronic acid boosts γδ T-cell activity in children receiving αβ+ T and CD19+ cell-depleted grafts from an HLA-haplo-identical donor A Bertaina, A Zorzoli, A Petretto, G Barbarito, E Inglese, P Merli, ... Oncoimmunology 6 (2), e1216291, 2017 | 72 | 2017 |
| Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2. CAR T-cells in patients with neuroblastoma N Tumino, G Weber, F Besi, F Del Bufalo, V Bertaina, P Paci, L Quatrini, ... Journal of hematology & oncology 14, 1-7, 2021 | 60 | 2021 |
| CD28. OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR. CD30 T cells M Guercio, D Orlando, S Di Cecca, M Sinibaldi, I Boffa, S Caruso, ... Haematologica 106 (4), 987, 2020 | 58 | 2020 |
| Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant E de Billy, M Pellegrino, D Orlando, G Pericoli, R Ferretti, P Businaro, ... Neuro-oncology 24 (7), 1150-1163, 2022 | 56 | 2022 |
| Safe and effective off-the-shelf immunotherapy based on CAR. CD123-NK cells for the treatment of acute myeloid leukaemia S Caruso, B De Angelis, F Del Bufalo, R Ciccone, S Donsante, G Volpe, ... Journal of Hematology & Oncology 15 (1), 163, 2022 | 55 | 2022 |
| Next-generation sequencing approaches for the identification of pathognomonic fusion transcripts in sarcomas: the experience of the Italian ACC sarcoma working group D Racanelli, M Brenca, D Baldazzi, F Goeman, B Casini, B De Angelis, ... Frontiers in Oncology 10, 489, 2020 | 51 | 2020 |
| Manipulating the metabolism to improve the efficacy of CAR T-cell immunotherapy M Pellegrino, F Del Bufalo, B De Angelis, C Quintarelli, I Caruana, ... Cells 10 (1), 14, 2020 | 47 | 2020 |
| Inclusion of the inducible caspase 9 suicide gene in CAR construct increases safety of CAR. CD19 T cell therapy in B-cell malignancies M Guercio, S Manni, I Boffa, S Caruso, S Di Cecca, M Sinibaldi, ... Frontiers in immunology 12, 755639, 2021 | 46 | 2021 |
Helen HeslopCenter for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and TexasПотвърден имейл адрес: bcm.edu